How does brolucizumab compare to aflibercept for treating diabetic macular edema over time?
Brolucizumab and aflibercept are both anti-VEGF drugs injected into the eye to treat diabetic macular edema (DME). Both can improve vision and reduce swelling, but they differ in dosing schedules and safety profiles. Brolucizumab may allow some patients to go longer between injections, but it has been linked to a higher risk of intraocular inflammation (IOI). Aflibercept is well-established with a longer track record and newer high-dose versions that also extend dosing intervals.
What the research says
In the KESTREL and KITE trials, brolucizumab 6 mg was noninferior to aflibercept 2 mg for vision improvement at 52 weeks. For example, in KITE, brolucizumab improved vision by +10.6 letters versus +9.4 letters for aflibercept 11. More patients on brolucizumab achieved a central subfield thickness below 280 µm and had less fluid in the retina, and over half maintained 12-week dosing intervals after loading 11. A post hoc analysis of the KINGFISHER study found that in patients previously treated for DME, brolucizumab improved vision by +11.0 letters versus +8.6 letters for aflibercept at 52 weeks 6. However, a global pharmacovigilance analysis reported that brolucizumab had the strongest association with intraocular inflammation among anti-VEGF agents (reporting odds ratio 633.32) 9. For aflibercept, newer 8 mg formulations (Eylea HD) have been approved for DME and can be given every 12 or 16 weeks after initial monthly doses, with comparable vision gains to the standard 2 mg every 8 weeks at 96 weeks 38. Biosimilar versions of aflibercept also show similar efficacy and safety to the reference drug 4.
What to ask your doctor
- Based on my eye health and treatment history, would brolucizumab or aflibercept be a better choice for me?
- What is the risk of intraocular inflammation with brolucizumab, and how would it be monitored?
- Could I be a candidate for the higher-dose aflibercept (Eylea HD) to reduce injection frequency?
- How do the costs and insurance coverage compare between these two medications?
- Are there any ongoing studies or newer treatments I should consider?
This question is drawn from common patient questions about Diabetes & Endocrinology and answered using cited medical research. We do not provide individualized advice.